admin | April 29, 2021
Here is a selection of presentations made during the American Society of Hematology annual meeting. To receive our review of the meeting by MPNRF Scientific Advisory John Crispino make sure to sign up for our free updates here.
- Gender is a Core Modifier of Disease Outcomes and Survival in the MPN https://ash.confex.com/ash/2015/webprogram/Paper86780.html
- PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks https://ash.confex.com/ash/2015/webprogram/Paper83413.html
- Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial https://ash.confex.com/ash/2015/webprogram/Paper79927.html
- Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia and Polycythemia Vera: Results after a Median 7-Year Follow-up of a Phase 2 Study https://ash.confex.com/ash/2015/webprogram/Paper82371.html
- Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs https://ash.confex.com/ash/2015/webprogram/Paper78903.html
- A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr-Mutated Low Risk Essential Thrombocythemia https://ash.confex.com/ash/2015/webprogram/Paper80134.html
- Pregnancy Outcomes in Patients with Myeloproliferative Neoplasms in the United Kingdom https://ash.confex.com/ash/2015/webprogram/Paper84823.html
- Pegylated-Interferon Treatment Is Safe and Efficient for Pregnant Patients with Essential Thrombocythaemia https://ash.confex.com/ash/2015/webprogram/Paper82990.html
- 59 Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results https://ash.confex.com/ash/2015/webprogram/Paper81328.html
- Dynamics of Mutations in Patients with ET Treated with Imetelstat https://ash.confex.com/ash/2015/webprogram/Paper81650.html